APA (7th ed.) Citation

CR, T., L, G., J, R., R, D., P, M., S, L., . . . S, U. (2026). Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England), 1. https://doi.org/10.1080/14796694.2026.2698699

Chicago Style (17th ed.) Citation

CR, Tan, et al. "Effectiveness of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd for Transplant-eligible Newly Diagnosed Multiple Myeloma." Future Oncology (London, England) 2026: 1. https://doi.org/10.1080/14796694.2026.2698699.

MLA (9th ed.) Citation

CR, Tan, et al. "Effectiveness of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd for Transplant-eligible Newly Diagnosed Multiple Myeloma." Future Oncology (London, England), 2026, p. 1, https://doi.org/10.1080/14796694.2026.2698699.